Blueprint Medicines Corp
NASDAQ:BPMC

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
NASDAQ:BPMC
Watchlist
Price: 94.63 USD 0.81% Market Closed
Market Cap: 6B USD
Have any thoughts about
Blueprint Medicines Corp?
Write Note

Blueprint Medicines Corp
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Blueprint Medicines Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Blueprint Medicines Corp
NASDAQ:BPMC
Operating Income
-$276m
CAGR 3-Years
12%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%
No Stocks Found

Blueprint Medicines Corp
Glance View

Market Cap
6B USD
Industry
Biotechnology

Blueprint Medicines Corp. is a precision therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 495 full-time employees. The company went IPO on 2015-04-30. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). The company is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The firm is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

BPMC Intrinsic Value
94.54 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Blueprint Medicines Corp's Operating Income?
Operating Income
-276m USD

Based on the financial report for Sep 30, 2024, Blueprint Medicines Corp's Operating Income amounts to -276m USD.

What is Blueprint Medicines Corp's Operating Income growth rate?
Operating Income CAGR 5Y
6%

Over the last year, the Operating Income growth was 48%. The average annual Operating Income growth rates for Blueprint Medicines Corp have been 12% over the past three years , 6% over the past five years .

Back to Top